Pieris Pharmaceuticals, Inc., a biotechnology company advancing novel bio therapeutics through its proprietary Anticalin® technology platform, entered into a research collaboration and license agreement with Roche in cancer immunotherapy (CIT).
Under the terms of the agreement, Pieris will discover, characterize and optimize Anticalin based drug candidates against an undisclosed target. Roche and Pieris will evaluate different drug formats against this target and advance them through preclinical development, with Roche being responsible for IND-enabling activities, clinical development and worldwide marketing of any resulting products.
Anticalin-branded proteins are engineered lipocalins, endogenous low-molecular weight human proteins typically found in blood plasma and other body fluids that naturally bind, store and transport a wide spectrum of molecules.
“Our partnership with Roche is a significant step forward for Pieris,” commented Stephen Yoder, President and CEO of Pieris. “The decision by the leader in the development and commercialization of cancer biologics to collaborate with Pieris underscores the unique potential of Anticalin-based proteins as a differentiated class of immuno-oncology drugs. As we initiate this collaboration, we will continue to vigorously advance our fully proprietary programs, including our lead CD137-HER2 bispecific.”
With its immuno-oncology PRS-300 Series Pieris is developing bispecific Anticalin-based protein therapeutics against a variety of tumor and immunomodulatory targets.
This collaboration represents Pieris’ first partnered immuno-oncology program and leverages Pieris’ capability to address a target in multiple ways through Anticalin-based drug candidates in different formats.